Education
About Us
Working with TipRanks
Follow Us
Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
RESEARCH TOOLSreports
Total Valuation
Concord Biotech Ltd. has a market cap or net worth of ₹196.39B. The enterprise value is ―.
Market Cap₹196.39B
Enterprise Value―
Share Statistics
Concord Biotech Ltd. has 104,616,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding104,616,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Concord Biotech Ltd.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Concord Biotech Ltd. is ―. Concord Biotech Ltd.’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Concord Biotech Ltd. had revenue of 9.98B and earned 3.08B in profits. Earnings per share was 29.45.
Revenue9.98B
Gross Profit7.53B
Operating Income6.26B
Pretax Income4.13B
Net Income3.08B
EBITDA4.66B
Earnings Per Share (EPS)29.45
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Concord Biotech Ltd. pays an annual dividend of ₹8.75, resulting in a dividend yield of 0.47%
Dividend Per Share₹8.75
Dividend Yield0.47%
Payout Ratio24.58%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change33.89%
50-Day Moving Average1.62K
200-Day Moving Average1.87K
Relative Strength Index (RSI)73.54
Average Volume (3m)12.43K
Important Dates
Concord Biotech Ltd. upcoming earnings date is Sep 3, 2025, TBA Not Confirmed.
Last Earnings DateMay 29, 2025
Next Earnings DateSep 3, 2025
Ex-Dividend DateJun 21, 2024
Financial Position
Concord Biotech Ltd. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Concord Biotech Ltd. has paid 1.04B in taxes.
Income Tax1.04B
Effective Tax Rate―
Enterprise Valuation
Concord Biotech Ltd. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Concord Biotech Ltd. has ₹2.82B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹2.82B billion.
Cash & Marketable Securities₹2.82B
Total Debt₹0.00
Net Cash-₹2.82B
Net Cash Per Share-₹26.92
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Concord Biotech Ltd. is ₹1,850.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹1,850.00
Price Target Upside10.98% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―